Media
News
Are you a media representative looking for content on Bayer? This section provides access to media releases as well as feeds from our social media channels.
Bayer’s darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival by 22 months, with a favourable safety profile compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer